Nutex Health, Inc.
NASDAQ:NUTXMedical - Healthcare Information Services
+$2.84 today
- Market cap
- $1.19B
- Beta
- 2.06
- P/E (TTM)
- 10.4
- EPS (TTM)
- $14.38
Volume 0.16M
Average 0.17M
NUTX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Nutex Health, Inc.NASDAQ: NUTX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $5.49M rose 7.9% year over year, ahead of the +5.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +16.1% a year.
Context
- Depreciation & amortization amounted to 2.3% of revenue in FY2025, down 1.6 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +7.9% holds above the trailing-twelve-month pace of +5.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 20.53M USD
- Year-over-year change
- +8.2%
- 4-year CAGR
- +27.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.53M | +8.2% |
| FY2024 | 2024-12-31 | 18.97M | +7.8% |
| FY2023 | 2023-12-31 | 17.59M | +34.0% |
| FY2022 | 2022-12-31 | 13.13M | +71.4% |
| FY2021 | 2021-12-31 | 7.66M | — |
Depreciation & Amortization vs competitors
How NUTX compares with its peers on the latest reported figures
- NUTX's LTM Mar 2026 depreciation & amortization of $20.93M is the 10th largest of the 11 companies compared; the peer median is $169.89M.
- Its year-over-year change of +5.3% is the 9th highest of 11, against a peer median of +10.1%.
- Depreciation & amortization amounts to 2.4% of revenue for NUTX, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $893M | +9.4% | +0.9% | 4.1% | |
| LTM Jun 2026 | $641.16M | +7.5% | +2.1% | 3.5% | |
| LTM Mar 2026 | $435M | -8.6% | -7.3% | 2.0% | |
| LTM Jun 2026 | $346.5M | +9.8% | +10.4% | 5.6% | |
| LTM Sep 2026 | $177.3M | +18.2% | +15.3% | 5.3% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $162.49M | +10.4% | +4.1% | 2.5% |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $79.99M | +12.4% | +1.0% | 3.4% |
| LTM Mar 2026 | $54.38M | +83.2% | +37.6% | 1.5% | |
| LTM Mar 2026 | $28.51M | +11.8% | +27.6% | 0.5% | |
| LTM Mar 2026 | $20.93M | +5.3% | +16.1% | 2.4% | |
| LTM Mar 2026 | $19.81M | -8.6% | +10.8% | 2.1% | |
| Peer median (excluding NUTX) | $169.89M | +10.1% | +7.2% | 3.0% | |
Competitors are the stored peer set for NUTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 168.53M | (432.74M) | (43.42M) | 95.27M | 180.36M |
| Depreciation & Amortization | 7.66M | 13.13M | 17.59M | 18.97M | 20.53M |
| Deferred Income Tax | 0 | 5M | (5.71M) | (13.13M) | 17.08M |
| Stock-Based Compensation | 0 | 189.58K | 2.84M | 16.63M | 117M |
| Change in Working Capital | 2.75M | 64.32M | (1.66M) | (104.4M) | (87.74M) |
| Accounts Receivables | (6.62M) | 58.08M | (4.58M) | (173.41M) | (89.32M) |
| Inventory | (1.09M) | (719.11K) | 142.7K | 540.77K | (16K) |
| Accounts Payables | 6.27M | 9.69M | (2.25M) | (10.72M) | 37.85M |
| Other Working Capital | 4.2M | (2.73M) | 5.03M | 79.19M | (36.26M) |
| Other Non-Cash Items | (5.51M) | 400.71M | 31.62M | 9.81M | 902K |
| Operating Cash Flow | 173.43M | 50.61M | 1.26M | 23.15M | 248.13M |
| Capital Expenditures | (36.93M) | (14.63M) | (9.5M) | (2.3M) | (2.53M) |
| Acquisitions (Net) | (48.85K) | 10.3M | (1.74M) | (361.33K) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 1.6M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (4.31M) |
| Investing Cash Flow | (36.98M) | (4.34M) | (11.24M) | (2.67M) | (5.24M) |
| Debt Repayment | (3.22M) | (5.59M) | 2.65M | (7.4M) | (19.44M) |
| Common Stock Issued | 0 | 4.76M | 0 | 9.2M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (5M) |
| Dividends Paid | (144.34M) | (51.23M) | (5.21M) | (6.44M) | (74.28M) |
| Other Financing Activities | 21.71M | 3.93M | 298.03K | 5.73M | 767K |
| Financing Cash Flow | (125.85M) | (48.13M) | (2.27M) | 1.09M | (97.95M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 10.6M | (1.86M) | (12.25M) | 21.58M | 144.93M |
| Free Cash Flow | 136.51M | 35.97M | (8.24M) | 20.85M | 245.6M |
Nutex Health, Inc.
NASDAQ:NUTX
Intrinsic Alpha fair value
Locked
Current Price
$172.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.